A Dendreon Options Trade: Hedging ASCO 2012 Data Releases
By Helix Investment Management:Without a doubt, Dendreon (DNDN) is one of the most controversial stocks in the market today. It seems that not a day goes by without a fierce debate over Provenge, its efficacy, and its future place in the prostate cancer market.Over the past year, Dendreon has suffered mightily, with the stock falling almost 82% as Provenge forecasts were cut and investors and analysts question the drug's role in treating prostate cancer going forward.
(click to enlarge)
But with a new CEO, John Johnson (appointed in February) and a turnaround plan in motion, could things finally be looking up for Dendreon? The market will soon be able to get a plethora of new information regarding Provenge and its place in the prostate cancer market. We believe that options can be used to substantially minimize the risk of investing in Dendreon, and outline our trade below. But first, an overview ofComplete Story »